1. Novel Concentrated Insulins: What Benefits and for Which Patients?

3. Program Goals

4. Guideline Recommendations for Treatment of T1DM

5. Pharmacokinetics of Commonly Used Insulins[a]

6. Insulin Development Timeline

7. Ultra-Fast-Acting Prandial Insulins: Clinical Development Approaches

8. Mean Serum Insulin Concentrations: Single Dose During a Euglycemic Clamp

9. Potential Impact and Consequences of Nocturnal Hypoglycemia

10. Timely Application of Insulin Therapy in T2DM

11. Commonly Prescribed Antihyperglycemics

12. Hazard Ratios for CV Outcomes: ORIGIN Trial—IGlar vs Standard of Care

13. Concentrated Insulins for SQ Use

14. Distribution of Insulin in SQ Tissue

15. IDeg U-200 vs IDeg U-100: Similar Time-Action Profiles

16. Reduced Hypoglycemic Events With Higher-Concentration Insulins: Results From the EDITION Trials

17. Prandial Insulins: Lispro U-100 and Lispro U-200: Similar Action Profiles

18. Concentrated Insulins: Target Patient Populations[a,b]

19. EDITION 3: Comparison of IGlar 300 U/mL vs IGlar 100 U/mL in Insulin-Naive Patients

20. BEGIN LOW VOLUME: IDeg 200 U/mL Once Daily Compared With IGlar

21. Medication Errors Associated With Use of Concentrated Insulins

22. BEGIN LOW VOLUME: Fewer Injections With IDeg

23. U-500R tid vs bid: Study Design

24. U-500R tid vs bid: HbA1c CFB

25. U-500R tid vs bid: Actual and CFB TDD Values

26. U-500 tid vs bid RCT: Body Weight CFB

27. U-500 tid vs bid: Severe Hypoglycemia, SAEs, TEAEs (0-24 Weeks)

28. Conversion Information for Humulin R U-500 (Concentrated) Insulin Dose

29. Sample Rx: U-500 Insulin, SQ Administration, 150-U Insulin Dose

30. Insulin Pen Delivery Systems

31. Summary